Inhibition of mTOR by Rapamycin Abolishes Cognitive Deficits and Reduces Amyloid-β Levels in a Mouse Model of Alzheimer's Disease

Patricia Spilman, Natalia Podlutskaya, Matthew J. Hart et al. · 2010

Read Inhibition of mTOR by Rapamycin Abolishes Cognitive Deficits and Reduces Amyloid-β Levels in a Mouse Model of Alzheimer's Disease by Patricia Spilman, Natalia Podlutskaya, Matthew J. Hart et al. (2010) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/plos-pone-0009979.txt.

Description

A drug used to stop organ rejection also quiets a master growth switch in the brain. Patricia Spilman and colleagues tested that drug in a mouse model of Alzheimer's disease. Their study appeared in PLOS ONE in 2010.

The drug is rapamycin, and the switch it blocks is mTOR. Inhibiting mTOR abolished cognitive deficits in the mice. Cognitive deficits mean losses in learning and memory. It also reduced amyloid-beta levels, the protein that clumps in Alzheimer's brains. One drug easing both symptoms and buildup drew wide attention. The mice were bred to develop Alzheimer's-like disease.

Catalog record

CREATORPatricia Spilman, Natalia Podlutskaya, Matthew J. Hart et al.
YEAR2010
COLLECTIONPAPERS
FORMATTXT
FILE SIZE39 KB
LICENSECreative Commons Attribution License
RIGHTSCC BY
SOURCEPLOS ONE

Source: https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0009979

Browse the full library · About the Tower of Babel